AstraZeneca and Daiichi Sankyo's Datroway improves OS in TNBC

6 October 2025

Positive high-level results have been presented on the specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) by Anglo-Swedish pharma major AstraZeneca (LSE: AZN) and Daiichi Sankyo (TYO: 4568) from the TROPION-Breast02 Phase III trial.

The results showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to investigator's choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), for whom immunotherapy was not an option.

We expect today’s results will mark an inflection point in the treatment of these patients

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK